Get the Stockscreener App
0.00
100.00%
-0.0123
Vincerx Pharma Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$0.0123
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-48.85M
P/E Ratio:
0.00
EPS:
-2.31
Net Cash Flow:
$-46.25M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-99.23%
1Y Performance:
-99.66%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.041
Vincerx Pharma Inc Stock (VINC) Company Profile
Compare VINC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VINC
Vincerx Pharma Inc
|
0.00 | 0 | 0 | -48.85M | -46.25M | -2.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-14-22 | Initiated | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-21 | Initiated | SVB Leerink | Outperform |
| Sep-13-21 | Initiated | Laidlaw | Buy |
| Aug-25-21 | Initiated | B. Riley Securities | Buy |
Vincerx Pharma Inc Stock (VINC) Latest News
Critical Review: Vincerx Pharma (NASDAQ:VINC) & Trevena (NASDAQ:TRVN) - Defense World
Reviewing Leap Therapeutics (NASDAQ:LPTX) and Vincerx Pharma (NASDAQ:VINC) - Defense World
Analyzing Vincerx Pharma (NASDAQ:VINC) & Petros Pharmaceuticals (NASDAQ:PTPI) - Defense World
Head to Head Analysis: Vectura Group (OTCMKTS:VEGPF) and Vincerx Pharma (NASDAQ:VINC) - Defense World
Vincerx Pharma, Inc. (VINC) Stock forecasts - Yahoo
Analyzing Neoleukin Therapeutics (NASDAQ:NLTX) & Vincerx Pharma (NASDAQ:VINC) - Defense World
Vincerx Pharma, Inc. (VINC) stock price, news, quote and history - Yahoo
Vincerx Pharma, Inc.Common Stock (NQ: VINC - FinancialContent
Vincerx Pharma ends sales agreement, approves reverse stock split - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VINC, NEUE, ZUO on Behalf of Shareholders - ACCESS Newswire
Vincerx Pharma (NASDAQ:VINC) vs. NovaBay Pharmaceuticals (NYSE:NBY) Financial Survey - Defense World
Vincerx Pharma, Inc. Announces Additional Adjournment of - GlobeNewswire
Vincerx Warns Stockholders: Delayed Dissolution Vote Threatens $0.07 Per Share DistributionAction Required - Stock Titan
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - The Manila Times
Vincerx announces potential distribution of $0.04-$0.08 per share By Investing.com - Investing.com South Africa
Vincerx announces potential distribution of $0.04-$0.08 per share - Investing.com
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR - GlobeNewswire
Vincerx Pharma Stockholders Face Critical July 16 Vote: $0.08 Per Share at Stake in Dissolution Plan - Stock Titan
Vincerx Pharma enters at-the-market equity offering deal - MSN
Vincerx Pharma, Inc. Announces Adjournment of Special MeetingWill Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal - Yahoo Finance
At a crossroads, biotechs are passing on reverse mergers in 2025 - Endpoints News
TC BioPharm’s $100M Shelf Offering: A Beacon of Resilience in a Collapsing Biotech Landscape - AInvest
VINC Stock Price and Chart — OTC:VINC - TradingView — Track All Markets
VINC stock touches 52-week low at $0.17 amid sharp annual decline - Investing.com
Nasdaq to delist Vincerx Pharma by April 23 - Investing.com India
vincerx pharma cancels merger, initiates wind-down activities - Investing.com
Vincerx's final merger attempt collapses, leaving ADC biotech to wind down - Fierce Biotech
Vincerx Pharma ends merger talks, begins asset wind-down - Investing.com
Vincerx Pharma Inc Initiates Wind Down and Asset Monetization - TipRanks
VINC Stock Plummets to 52-Week Low of $0.48 Amid Steep Decline - Investing.com
Vincerx Pharma Inc. (VINC) reports earnings - qz.com
Vincerx Pharma Inc expected to post a loss of $3.40 a shareEarnings Preview - TradingView
Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis - Fierce Biotech
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - insights.citeline.com
Cash-strapped Vincerx left mulling future after Oqory reverse merger falls apart - Fierce Biotech
Vincerx Pharma, Inc. Terminates Reverse Merger Agreement and Will Explore Strategic Alternatives - Nasdaq
VINC stock touches 52-week low at $1.3 amid market challenges - Investing.com
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 - Yahoo Finance
Vincerx Pharma, Inc. Announces 1-for-20 Reverse Stock Split Effective January 27, 2025 - Nasdaq
Palo Alto's Vincerx Pharma plans reverse stock split amid merger plans - The Business Journals
Vincerx Pharma, Inc. Announces Reverse Stock Split - GlobeNewswire
Vincerx Pharma ends sales agreement, approves reverse stock split By Investing.com - Investing.com UK
Investor law firms question biotech merger's 'fairness' - The Business Journals
Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc.VINC | FinancialContent - FinancialContent
Vincerx acquisition leads to C-suite shake-up—Chutes & Ladders - Fierce Biotech
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
PRN_FinancialWrapper - FinancialContent
Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish - Stocktwits
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - Yahoo Finance
Vincerx Pharma Stock Gets Retail Followers Buzzing With Big Layoff Plans To Sustain Cancer Drug Trials - Stocktwits
Vincerx Pharma Reports Promising Cancer Drug Results, Explores Strategic Options Amid Cost Cuts - Stock Titan
Vincerx Pharma Inc Stock (VINC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Cap:
|
Volume (24h):